Published in Br Med J on March 02, 1974
Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians (1969) 2.15
Relation of prolactin and estrogen to mammary tumorigenesis in the rat. J Natl Cancer Inst (1972) 1.23
Oestrogen receptor in human breast cancer tissue and response to endocrine therapy. Br Med J (1973) 1.21
Circadian periodicity of serum prolactin concentration in man. Br Med J (1972) 1.18
Hormonal therapy in cancer of the breast. VII. Effect of conjugated estrogens (equine) on clinical course and hormonal excretion. Cancer (1954) 1.13
Hypothesis: breast cancer regression under oestrogen therapy. Br Med J (1973) 1.13
Anti-oestrogens and breast cancer. Eur J Cancer (1971) 1.04
Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer (1962) 0.97
Pituitary function and hormonal therapy of experimental breast cancer. Cancer Res (1965) 0.95
Two modes of interaction between oestrogen and anti-oestrogen. Acta Endocrinol (Copenh) (1970) 0.84
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab (1990) 1.81
Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154). Obstet Gynecol (1976) 1.68
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther (1976) 1.39
Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer. Eur J Cancer (1977) 1.37
Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res (1972) 1.35
Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res (1972) 1.27
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
Estrogen receptors in human breast cancer. Eur J Cancer (1973) 1.24
Prolactin release after injection of thyrotrophin-releasing hormone in man. Lancet (1972) 1.23
Circadian periodicity of serum prolactin concentration in man. Br Med J (1972) 1.18
The influence of exogenous estrogen on the circadian periodicity of circulating prolactin in women. J Clin Endocrinol Metab (1975) 1.18
Epidemiology of pregnancies with unknown last menstrual period. J Epidemiol Community Health (1984) 1.18
Oestrogen receptors in breast cancer: a changing concept. Br Med J (1975) 1.16
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
The cardiotoxicity of anticancer agents. Semin Oncol (1982) 1.15
Radioimmunoassay of a human pituitary prolactin in plasma. Hormones (1971) 1.15
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol (1986) 1.14
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13
[Human pituitary prolactin: radioimmunologic detection and level during pregnancy]. Ann Endocrinol (Paris) (1973) 1.10
Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg (1980) 1.08
Serum levels of intact human chorionic gonadotropin (HCG) and its free alpha and beta subunits, in relation to maternal thyroid stimulation during normal pregnancy. J Endocrinol Invest (1993) 1.05
Quantitative analysis of spontaneous variations of plasma prolactin in normal man. Am J Physiol (1981) 1.05
Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol (Oxf) (1983) 1.04
Radioimmunoassay of human follicle-stimulating hormone with antisera to the ovine hormone. J Clin Endocrinol Metab (1971) 1.04
Assay for estrogen and progesterone receptors of breast cancer cell lines in monolayer culture. Eur J Cancer Clin Oncol (1985) 1.03
Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur J Cancer (1977) 1.00
Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer (1977) 1.00
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer (1980) 1.00
Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women. Eur J Cancer (1973) 0.98
Influence of age on serum prolactin levels in women and men. Br Med J (1975) 0.98
Long-term survivors with small cell carcinoma of the lung. Eur J Cancer (1980) 0.95
The role of antitumor antibiotics in current oncologic practice. Cancer Chemother Pharmacol (1978) 0.95
Estrogenic and antiestrogenic down-regulation of estrogen receptor levels: evidence for two different mechanisms. J Recept Res (1990) 0.94
Estradiol-dependent collagenolytic enzyme activity in long-term organ culture of human breast cancer. Cancer Res (1975) 0.94
The chemotherapy of Hodgkin's disease: past experiences and future directions. Cancer (1978) 0.93
Physiological and pharmacological effects of estrogens in breast cancer. Biochim Biophys Acta (1979) 0.93
The use of peritoneoscopy in the detection of liver metastases. Cancer (1978) 0.93
Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol (1989) 0.93
Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist. Gynecol Invest (1971) 0.92
Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study. Br Med J (1975) 0.92
Carboplatin: current status and future prospects. Cancer Treat Rev (1988) 0.91
Overview of Taxol safety. J Natl Cancer Inst Monogr (1993) 0.91
Facilitation of rat mammary tumour growth by BCG. Nature (1970) 0.91
Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study. Br Med J (1975) 0.91
Serum prolactin, gonadotropins, and estradiol in menstruating and amenorrheic mothers during two years' lactation. Am J Obstet Gynecol (1978) 0.91
[Evolution of serum prolactin levels during menstrual cycle]. C R Acad Sci Hebd Seances Acad Sci D (1972) 0.91
Serum prolactin levels during the menstrual cycle. J Clin Endocrinol Metab (1977) 0.90
Assessment of response to therapy in advanced breast cancer (an amendment) Br J Cancer (1978) 0.90
Comparative immunoenzymatic localization of prolactin and growth hormone in human and rat pituitaries. J Histochem Cytochem (1976) 0.89
Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol (1983) 0.89
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol (2014) 0.89
Rapid electrotransfer of proteins from polyacrylamide gel to nitrocellulose membrane using surface-conductive glass as anode. Anal Biochem (1985) 0.88
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) (1992) 0.88
Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep (1983) 0.88
Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer (1988) 0.88
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol (1979) 0.88
[Simultaneous study of circadian variations of blood thyrotropin (TSH) and pituitary prolactin levels in man]. C R Acad Sci Hebd Seances Acad Sci D (1973) 0.88
VM 26 and VP 16-213: a comparative analysis. Cancer (1977) 0.88
Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials (1981) 0.87
cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity. Adv Pharmacol Chemother (1979) 0.87
Effect of Bacillus Calmette-Guérin on mammary tumor formation and cellular immunity in dimethylbenz(a)anthracene-treated rats. Cancer Res (1971) 0.86
m-AMSA and PALA: two new agents in cancer chemotherapy. Cancer Chemother Pharmacol (1979) 0.86
Anthracycline derivatives in new drug development programs. Cancer Treat Rep (1979) 0.86
Gonadotropins and prolactin pituitary reserve in premature thelarche. J Pediatr (1977) 0.85
Effect of insulin on DNA synthesis and DNA polymerase activity in organ culture of rat mammary carcinoma, and the inflence of insulin pretreatment and of alloxan diabetes. Cancer Res (1971) 0.85
Effect of progesterone on cell proliferation in the MXT mouse hormone-sensitive mammary neoplasm. J Natl Cancer Inst (1986) 0.85
In vitro growth of human malignancies in a cloning assay. Recent Results Cancer Res (1984) 0.85
Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-alpha-ergocryptine, a suppressor of lactation and nidation. Eur J Cancer (1970) 0.85
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. J Clin Oncol (1984) 0.84
Prolactin and thyrotropin in thyroid diseases: lack of evidence for a physiological role of thyrotropin-releasing hormone in the regulation of prolactin secretion. Horm Metab Res (1974) 0.84
Time course of physiological hyperprolactinaemia during two years lactation. Clin Endocrinol (Oxf) (1977) 0.84
Effects of glucocorticoids on pituitary hormonal responses to hypoglycemia. Inhibition of prolactin release. J Clin Endocrinol Metab (1975) 0.84
Oestrogen receptors in male breast cancer. Biomedicine (1976) 0.84
Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep (1976) 0.84
EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma. Eur Urol (1976) 0.84
Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo. Eur J Cancer (1970) 0.83
Chemotherapy of testicular cancer: from palliation to curative adjuvant therapy. Semin Oncol (1979) 0.83
Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas (1988) 0.83
Effects on insulin, prolactin, progesterone, and estradiol on DNA synthesis in organ culture of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Cancer Res (1976) 0.83
Daunomycin: an anthracycline antibiotic effective in acute leukemia. Adv Pharmacol Chemother (1978) 0.83
Serum levels of prolactin and milk production in women during a lactation period of thirty months. Clin Endocrinol (Oxf) (1981) 0.83